Comment on CMS-2026-1255-0001
American Diabetes AssociationSupportAdvocacy
Summary: The American Diabetes Association (ADA) supports the proposed rule to streamline and automate prior authorization processes for drugs, specifically requesting the inclusion of clear denial reasons and reporting metrics. However, the organization urges CMS to go further by reducing the total number of services subject to prior authorization, eliminating step therapy for Part B drugs, and creating explicit exceptions for diabetes medications.
The American Diabetes Association (ADA) wishes to provide comments in response to the Interoperability Standards and Prior Authorization for Drugs proposed rule.
See attached file(s)